Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Encore Pharmaceuticals has received a grant from a division of the US National Institute of Health to continue the development of its lead drug candidate for treatment of the neuro-inflammatory disorders, amyotrophic lateral sclerosis, and Huntington's disease.
Subscribe to our email newsletter
The $750,000 grant award will support continued collaborative research and development between EncorePharma and researchers at the Oklahoma Medical Research Foundation (OMFR).
In addition, the phase 2 grant award will support the ongoing effort of EncorePharma and its collaborators to identify natural products and natural-product-derived small molecules for use in large-market neurodegenerative diseases such as Alzheimer’s disease.
“This award further validates the research work that has been conducted over the last 18 months and was partially supported by an SBIR phase 1 grant. We will now move quickly into the first stages of pre-clinical development with E-8110, our first lead therapeutic candidate in this area,” stated Dr Barbara Loughman, president of EncorePharma.